Drug-induced torsade de pointes: From molecular biology to bedside

Japanese Journal of Pharmacology

Volumn 83, Issue 1, 2000, Pages 1-19

  Tamargo, Juan ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Cardiac arrhythmia; HERG (human ether a go go related gene); Long QT syndrome; MiRP1 (MinK related peptide 1); Potassium channel; Torsade de pointes

Indexed keywords

AMANTADINE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; COTRIMOXAZOLE; DIURETIC AGENT; IMIDAZOLE; KETANSERIN; LIDOCAINE; MACROLIDE; MEXILETINE; NEUROLEPTIC AGENT; PENTAMIDINE; PEPTIDE; PERHEXILINE; POTASSIUM CHANNEL; PSYCHOTROPIC AGENT; QUINIDINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SILDENAFIL; TETRACYCLIC ANTIDEPRESSANT AGENT; TRIAMTERENE; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; UNINDEXED DRUG; VASODILATOR AGENT; VINCAMINE; ZIMELDINE;

ANTIARRHYTHMIC ACTIVITY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; GASTROESOPHAGEAL REFLUX; HEART ARRHYTHMIA; HEART DEATH; HEART VENTRICLE FIBRILLATION; HUMAN; IATROGENIC DISEASE; INFECTION; LONG QT SYNDROME; MENTAL DISEASE; MUSCLE ACTION POTENTIAL; NONHUMAN; REVIEW; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFECTIVE AGENTS; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNELS; PSYCHOTROPIC DRUGS; RISK FACTORS; TORSADES DE POINTES;

EID: 0034036880     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.83.1     Document Type: Review

References (170)

1. Gutgesell H, Atkins D, Barst R, Buck M, Franklin W, Humes R, Ringel R, Shaddy R and Tauber K: Cardiovascular monitoring of children and adolescents receiving psychotropic drugs. A statement for healthcare professionals from the Committee on Congenital Cardiac Defect, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 99, 979-982 (1999)
2. Jackman W, Friday K, Anderson J, Aliot E, Clark M and Lazzara R: The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 31, 115-172 (1988)
3. Haverkamp W, Shenasa M, Borggrefe M and Breithardt G: Torsade de pointes. In Cardiac Electrophysiology: from Cell to Bedside, Edited by Zipes DP and Jalife J, Second ed, pp 885-899, Saunders, Philadelphia, PA (1995)
4. Tan H, Hou C, Lauer M and Sung R: Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 122, 701-714 (1995)
5. Roden D, Lazzara R, Rosen M, Schwartz P, Towbin J, Vincent M, for the SADS Foundation Task Force on LQTS: Multiple mechanisms in the Long-QT syndrome. Current knowledge, gaps, and future directions. Circulation 94, 1996-2012 (1996)
6. Virgin S: Long QT syndromes and torsades de pointes. Lancet 354, 1625-1633 (1999)
7. Vincent G: The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med 49, 263-274 (1998)
8. Viskin S and Belhassen B: Polymorphic ventricular tachyarrhythmias in the absence of organic heart disease: Classification, differential diagnosis, and implications for therapy. Prog Cardiovasc Dis 41, 17-34 (1998)
9. Kay G, Plumb V, Arciniegas J, Henthorn R and Waldo A: Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 2, 806-817 (1983)
10. Carmeliet E and Mubagwa K: Antiarrhythmic drugs and cardiac ion channels: mechanisms of action. Prog Biophys Mol Biol 70, 1-72 (1998)
11. Roden D and George A Jr: Structure and function of cardiac sodium and potassium channels. Am J Physiol 273, H511-H525 (1997)
12. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96, 195-215 (1990)
13. Delpón E, Valenzuela C and Tamargo J: Blockade of cardiac potassium and other channels by antihistamines. Drug Safety 21, Suppl 1, 11-18 (1999)
14. + channels. Ann NY Acad Sci 868, 233-285 (1999)
15. Priori S, Barhanin J, Hauer R, Haverkamp W, Jongsma H, Kleber A, McKenna W, Roden D, Rudy Y, Schwanz K, Schwartz PJ, Towbin JA and Wilde A: Genetic and molecular basis of cardiac arrhythmias. Impact on clinical management. Eur Heart J 20, 174-195 (1999)
16. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97, 175-187 (1999)
17. Ks potassium channel. Nature 384, 80-83 (1996)
18. Splawski I, Timothy K, Vincent G, Atkinson D and Keating M: Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med 336, 1562-1567 (1997)
19. Kr potassium channel. Cell 81, 299-307 (1995)
20. Curran M, Splawski I, Timothy K, Vincent G, Green E and Keating M: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795-803 (1995)
21. + channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci USA 93, 2208-2212 (1996)
22. Kiehn J, Lacerda, Wible B and Brown A: Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 94, 2572-2579 (1996)
23. Suessbrich H, Waldegger S, Lang F and Busch A: Blockade of HERG channel expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 385, 77-80 (1996)
24. + channel. Open-channel block by methanesulfonanilides. Circ Res 78, 499-503 (1996)
25. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273, H2534-H2538 (1997)
26. Rampe D, Murawsky M, Grau J and Lewis E: The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286, 788-793 (1998)
27. Busch A, Eigenberger B, Jurkiewicz N, Salata J, Pica A, Suessbrich H and Lang F: Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action. Br J Pharmacol 123, 23-30 (1998)
28. Kr: implication for torsade de pointes and reverse use-dependence. Circulation 93, 407-411 (1996)
29. Surawicz B: Electrophysiologic substrate of torsade de pointes. Dispersion of repolarization or early afterdepolarizations. J Am Coll Cardiol 14, 172-184 (1989)
30. Ben David J and Zipes D: Torsades de pointes and proarrhythmia. Lancet 341, 1578-1582 (1993)
31. Viswanathan P and Rudy Y: Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. Cardiovasc Res 42, 530-542 (1999)
32. El Sherif N, Craelius W, Boutjdir M and Gough W: Early afterdepolarizations and arrhythmogenesis. J Cardiovasc Eletrophysiol 1, 145-160 (1990)
33. Eckardt L, Haverkamp W, Borggrefe M and Breithardt G: Experimental models of torsade de pointes. Cardiovasc Res 39, 178-193 (1998)
34. Nattel S: Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 37, 567-577 (1998)
35. 1-adrenergic receptor subtypes. Cardiovasc Res 27, 839-844 (1993)
36. Antzelevitch C and Sicouri S: Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves triggered activity and torsade de pointes. J Am Coll Cardiol 23, 259-277 (1994)
37. Antzelevitch C, Sun Z, Zhang Z and Van G: Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 28, 1836-1848 (1996)
38. Ks) in canine ventricular epicardial, mid-myocardial, and endocardial myocytes. Circ Res 76, 351-365 (1995)
39. Hii J, Wyse D, Gillis A, Duff H, Solylo M and Mitchell L: Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 86, 1376-1382 (1992)
40. El Sherif N, Caref E, Yin H and Restivo M: The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome tridimensional mapping of activation and recovery patterns. Circ Res 79, 474-492 (1996)
41. Roden D, Woosley R and Primm R: Incidence and clinical feature of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111, 1088-1093 (1986)
42. Hohnloser S and Meinertz T: Recorded sudden cardiac death: relationship to antiarrhythmic therapy. Eur Heart J 9, Suppl B, 27-31 (1988)
43. Wald R, Waxman M and Colman J: Torsade de pointes ventricular tachycardia: a complication of disopyramide shared with quinidine. J Electrocardiol 14, 301-308 (1981)
44. Strasberg B, Sclarovsky S, Erdberg A, Duffy C, Lam W, Swiryn S, Agmon J and Rosen K: Procainamide-induced polymorphous ventricular tachycardia. Am J Cardiol 47, 1309-1314 (1981)
45. Scagliotti D, Strasberg B, Hai H, Kehoe R and Rosen K: Aprindine-induced polymorphous ventricular tachycardia. Am J Cardiol 49, 1297-1300 (1982)
46. Kaul U, Mohen J, Narula J and Bathia M: Ajmaline-induced torsade de pointes. Cardiology 72, 140-143 (1985)
47. Krebs M, Szwed J, Shinn T, Miles W and Zipes D: Short-term rapid ventricular pacing prolongs ventricular refractoriness in patients. J Cardiovasc Electrophysiol 8, 1036-1042 (1998)
48. Po S, Wang D, Yang I, Johnson J Jr, Nie L and Bennett P: Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol 33, 181-185 (1999)
49. Choy A, Lang C, Chomsky D, Rayos G, Wilson J and Roden D: Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 96, 2149-2154 (1997)
50. Nattel S, Ranger S, Talajic M, Lemery R and Roy D: Erythomycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 89, 235-238 (1990)
51. Tamargo J, Valenzuela C and Delpón E: New insights into the pharmacoloy of sodium channel blockers. Eur Heart J 13, Suppl F, 2-13 (1992)
52. K, by flecamide and E-4031 in cat ventricular myocytes. Circulation 82, 289-293 (1990)
53. + current in guinea-pig ventricular myocytes. Voltage-independent and time-dependent block of the slowly activating component. Circ Res 76, 223-235 (1995)
54. Delgado C, Tamargo J, Tejerina T and Valenzuela C: Effect of 5-hydroxy-propafenone in guinea-pig atrial fibres. Br J Pharmacol 90, 575-582 (1987)
55. Winkle R, Mason J, Griffin J and Ross D: Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 102, 857-864 (1981)
56. Sanguinetti M and Salata J: Cardiac potassium channel modulators: Potential for antiarrhythmic therapy. In Potassium Channels and their Modulators. From Synthesis to Clinical Experience, Edited by Evans J, Hamilton T, Longman S and Stemp G, pp 221-256, Taylor & Francis, London (1996)
57. Liu S, Rasmusson RL, Campbell DL Wang S and Strauss HC: Activation and inactivation kinetics of an E-4031-sensitive current from single ferret atrial myocytes. Biophys J 70, 2704-2715 (1996)
58. Kr. Circulation 94, 2928-2946 (1996)
59. Suessbrich H, Schönherr R, Heinemann S, Lang F and Busch A: Specific block of cloned HERG channels by clofilium and its tertiary analog LY97241. FEBS Lett 414, 435-438 (1997)
60. Arena J and Kass R: Block of heart potassium channels by clofilium and its tertiary analogs: Relationship between drug structure and type of channel blocked. Mol Pharmacol 34, 60-66 (1988)
61. + current by almokalant in rabbit ventricular myocytes. Circ Res 73, 857-868 (1993)
62. Salata J and Brooks R: Pharmacology of azimilide dihydrochloride (NE-10064). Cardiovasc Drug Rev 15, 137-156 (1997)
63. Zhang Z-H, Follmer C, Sarma J, Chen F and Singh B: Effect of ambasilide, a new class III agent, on plateau currents in isolated guinea pig ventricular myocytes: Block of delayed outward potassium current. J Pharmacol Exp Ther 263, 40-48 (1992)
64. Kr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation 91, 1799-1806 (1995)
65. + currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther 254, 560-569 (1990)
66. Kiehn J, Thomas D, Karle C, Schöls W and Kübler W: Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERO potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359, 212-219 (1999)
67. Kodama I, Kamiya K and Toyama J: Cellular electropharmacology of amiodarone. Cardiovasc Res 35, 13-29 (1997)
68. Ks, in guinea-pig isolated ventricular myocytes. Exp Physiol 81, 587-603 (1996)
69. sk channels expressed in Xenopus oocytes by calmodulin antagonists. Eur J Pharmacol 259, 335-338 (1994)
70. + current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res 75, 879-886 (1994)
71. Busch A, Suessbrich H, Waldgger S, Sailer E, Greger R, Lang H-J, Gibson K and Maylie J: Inhibition of IKs in guinea pig cardiac myocytes and guinea pig Isk channels by the chromanol 293B. Pflugers Arch 432, 1094-1096 (1996)
72. Singh B: Antiarrhythmic drugs: A reorientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 81 (6A), 3D-13D (1998)
73. Hondeghem L and Snyders D: Class III antiarrhythmic agents have a lot of potential, but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation 81, 686-690 (1990)
74. Abrahamsson C, Palmer M, Ljung B, Duker G, Baarnhielm C, Carlsson L and Danielsson B: Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Cardiovasc Res 28, 337-344 (1994)
75. MacNeil D, Davies R and Deitchman D: Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 72, Suppl, 44A-50A (1993)
76. Karam R, Marcello S, Brooks R, Corey A and Moore A: Azimilide dihydrochloride, a novel antiarrhythmic agent. Am J Cardiol 81 (6A), 40D-46D (1998)
77. Houltz B, Darpo B, Edvardsson N, Blomstom P, Brachman J, Crijns H, Jensen S, Svernhage E, Vallin H and Edvardsson N: Electrocardiographic and clinical predictors of torsade de pointes induced by almokalant infusion in patients with chronic atrial fibrillation and nutter. PACE 21, 1044-1057 (1998)
78. Wiesfeld A, Crinjs H, Bergstrand H, Almgren O, Hillege H and Lie K: Torsade de pointes with almokalant, a new class III antiarrhythmic drug. Am Heart J 126, 1008-1011 (1993)
79. Hohnloser S, Klingenheben T and Singh B: Amiodarone-associated proarrhythmic effects: a review with special reference to torsades de pointes tachycardia. Ann Intern Med 121, 529-535 (1994)
80. Mattioni T, Zheutlin T, Sarmiento J, Parker M, Lesch M and Kehue R: Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. Ann Intern Med 111, 574-580 (1989)
81. Sager P, Uppal P, Follmer C, Antimisiaris M, Pruitt C and Singh B: Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 88, 1063-1071 (1993)
82. Zipes D: The long QT interval syndrome. A Rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation 84, 1414-1419 (1991)
83. Zhang S, Zhou Z, Gong Q, Makielski J and January C: Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84, 989-998 (1999)
84. Keren A, Tepper D, Butler B, Maguire W, Willens H, Miura D and Somberg J: Studies on the possible mechanisms of lidoflazine arrhythmogenicity. J Am Coll Cardiol 4, 742-747 (1984)
85. Riccioni N, Bartolomei C and Soldani S: Prenylamine-induced ventricular arrhythmias and syncopal attacks with Q-T prolongation. Cardiology 66, 199-203 (1980)
86. Guillou M, Carious A, Blanc J, Boschat J, Granatelli D and Penther P: Torsades de pointe. Responsabilité eventuelle d'un vasodilateur péripherique: le fenoxedil. Nouv Presse Med 4, 2118 (1975) (in French)
87. Singh B: Safety profile of bepridil determined from clinical trials in chronic stable angina in the United States. Am J Cardiol 69, 68D-74D (1992)
88. Dany F, Liozon F, Goudoud J, Castel J, Michel J, Marsaud P, Merle L and Dalloccio M: Torsades de pointes et arrythmies ventriculaires graves per administration parenterale de vincamine. Arch Mal Coeur 73, 298-306 (1980) (text in French with English abstract)
89. Vrolix M, Piessens J and De Geest H: Torsade de pointes after intracoronary papaverine. Eur Heart J 12, 273-276 (1991)
90. Walker B, Valenzuela S, Slingleton C, Tie H, Bursill J, Wyse K, Qiu M, Breit S and Campbell T: Inhibition of HERG channels stable expressed in mammalian cell line by the antianginal agent perhexiline maleate. Br J Pharmacol 127, 243-251 (1999)
91. Le Grand B, Talmant J, Rieu J, Patoiseau J, Colpaert F and John G: Investigation of the mechanism by which ketanserin prolongs the cardiac action potential duration. J Cardiovasc Pharmacol 26, 803-809 (1995)
92. Aldariz A, Romero H, Baroni M, Bablivo H and Esper R: QT prolongation and torsades de pointes ventricular tachycardia produced by ketanserin. PACE 9, 836-841 (1986)
93. K) by the 5-HT3 antagonists ondansetron and granisetron in feline ventricular myocytes. Br J Pharmacol 113, 527-535 (1994)
94. Williams P, Cohen M and Turk J: Electrocardiographic effects of zatosetron and ondansetron, two 5HT3 receptor antagonists in anesthetized dogs. Drug Dev Res 24, 277-284 (1991)
95. Liljeqvist J and Edvardsson N: Torsade de pointes tachycardias induced by overdosage of zimeldine. J Cardiovasc Pharmacol 14, 666-670 (1989)
96. Wisowski D and Bacsanyi J: Cisapride and fatal arrhythmia. N Engl J Med 335, 290-295 (1996)
97. Wilens T, Diederman J, Baldessarini R, Geller B, Schleifer D, Spencer T, Birmaher B and Goldblatt A: Cardiovascular effects of therapeutic doses tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 35, 1491-1501 (1996)
98. Warner J, Barnes T and Henry J: Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiat Scand 93, 311-313 (1996)
99. + current activation in guinea pig ventricular myocytes. Circ Res 74, 687-699 (1994)
100. Teschemacher A, Seward J, Hancox J and Witchel H: Inhibition of the current heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128, 479-485 (1999)
101. Suessbrich H, Schönherr S, Attali R, Lang F and Busch A: The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 120, 968-974 (1997)
102. Drolet B, Vincent F, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin B and Turgeon J: Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288, 1261-1268 (1999)
103. Davison E: Amitriptyline-induced torsade de pointes. Successful therapy with atrial pacing. J Electrocardiol 18, 299-302 (1985)
104. Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R and Rosen K: Doxepin induced torsade de pointes. PACE 5, 873-877 (1982)
105. Herrmann H, Kaplan L and Bierer B: Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol 51, 904-906 (1983)
106. Janowsky D, Lurtis G, Zisook S, Kuhn K, Revovsky K and Winter M: Ventricular arrhythmias possibly aggravated by trazodone. Am J Psychiatry 140, 796-797 (1983)
107. Guy J, Andre Fouet X, Porte J, Bertrand M, Lamaud M and Verneyre H: Torsades de pointes and prolongation of the duration of QT interval following the injection of droperidol. Ann Cardiol Angeiol (Paris) 40, 541-545 (1991) (text in French with English abstract)
108. Kriwisky M, Perry GY, Tarchitsky D and Kishon Y: Haloperidol-induced torsades de pointes. Chest 98, 482-484 (1990)
109. Zimbroff D, Kane J, Tamminga C, Daniel D, Mack R, Wozniak P, Sebree T, Wallin B and Kashkin K: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154, 782-791 (1997)
110. Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA and Meier P: Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 309, 315-316 (1995)
111. Young J, Vandermolen L and Pratt C: Torsade de pointes: an unusual manifestation of chloral hydrate poisoning. Am Heart J 112, 181-184 (1986)
112. Shi W, Wymore R, Wang H, Pan Z, Cohen I, McKinnon D and Dixon J: Identification of two nervous system-specific members of the erg potassium channel gene family. J Neurosci 17, 9423-9432 (1997)
113. Woosley R: Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 36, 233-252 (1996)
114. Salata J, Jurkiewicz N, Wallace A, Stupienski R, Guinosso P and Lynch J: Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 76, 110-119 (1995)
115. Pinto Y, Van Gelder I, Heeringa M and Crijns H: QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 353, 980 (1999)
116. Lindquist M and Edwards I: Risks of non-sedating antihistamines. Lancet 349, 1322 (1997)
117. Oberg K and Bauman J: QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 15, 687-692 (1995)
118. Lee KL, Jim MH, Tang SC and Tai YT: QT prolongation and torsades de pointes associated with clarithromycin. Am J Med 104, 395-396 (1998)
119. Daleau P, Lessard E, Groleau M-F and Turgeon J: Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Circulation 91, 3010-3016 (1995)
120. Stramba-Badiale M, Nador F, Porta N, Fugganti S, Frediani M, Colnaghi C, Grancini F, Motta G, Carnelli V and Schwartz P: QT interval prolongation and risk of life-threatening arrhythmias during toxoplasmosis prophylaxis with spiramycin in neonates. Am Heart J 133, 108-111 (1997)
121. Lopez J, Harold J, Rosenthal M, Osevan D, Schapira J and Peter T: QT prolongation and torsade de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 59, 376-377 (1986)
122. Wharton J, Demopoulos P and Goldschlager N: Torsade de pointes during administration of pentamidine isethionate. Am J Med 83, 571-576 (1987)
123. Fauchier JP, Lanfranchi J, Ginies G and Raynaud R: Syncope par torsade de pointe au cours d'un traitement par la chloroquine. Étude de l'electrogramme Hisier et traitement par le verapamil. Ann Cardiol Angeiol (Paris) 23, 341-346 (1974) (in French)
124. Nosten F, ter Kuile F, Luxemberg C, Woodrow C, Kyle D, Chogsuphajaisiddhi T and White N: Cardiac effects of antimalarial treatment with halofantrine. Lancet 341, 1054-1056 (1993)
125. Sartori M, Pratt C and Young J: Torsade de pointe. Malignant cardiac arrhythmia induced by amantadine poisoning. Am J Cardiol 77, 388-391 (1984)
126. Slaughter R and Edwards D: Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29, 619-624 (1995)
127. Dumaine R, Roy M and Brown A: Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther 286, 727-735 (1998)
128. K) in guinea pig ventricular myocytes. Circ Res 74, 1114-1120 (1994)
129. Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, Kamakura S, Matsuhisa M and Shimomoura K: Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 84, 1915-1923 (1991)
130. McDonald T, Pelzer S, Trautwein W and Pelzer D: Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiol Rev 74, 365-507 (1994)
131. Members of the Sicilian Gambit: Molecular targets for drug action. In Antiarrhythmic Therapy: A Pathophysiologic Approach, pp 11-24, Futura Publishing Co, Inc, London (1994)
132. Beckman K, Bauman L, Pimentai P and Hariman R: Arsenic-induced torsade de pointes. Crit Care Med 19, 290-292 (1991)
133. Ludomirsky A, Klein H, Sarelli P, Becker B, Hoffman S, Taitelman U, Barzilai J, Lang R, David D, Di Segni E and Kaplinsky E: Q-T prolongation and polymorphous (torsades de pointes) ventricular arrhythmias associated to organophosphorous insecticide poisoning. Am J Cardiol 49, 1654-1658 (1982)
134. Wolf G and Hirschfeld J: Changes in QTc interval induced with Renographin-76 and Hypaque-76 during coronary angioplasty. J Am Coll Cardiol 1, 1489-1492 (1983)
135. Hirata K, Kyushima M, Kaeamitsu K, Asato H, Sunagawa H and Uehara H: A case of torsades de pointes probably caused by trimetaphan intoxication. J Cardiol 24, 243-247 (1994)
136. Bender K, Shematek J, Leventhal B and Kan J: QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 105, 442-444 (1984)
137. James M, Culling W and Vann J: Polymorphous ventricular tachycardia due to alpha blockade. Int J Cardiol 14, 225-227 (1987)
138. Gohn D and Simmons T: Polymorphic ventricular tachycardia (torsade de pointes) associated with the use of probucol. New Engl J Med 326, 1435-1436 (1992)
139. Schrem S, Belsky P, Schwartzman D and Slater W: Cocaine-induced torsades de pointes in a patient with idiopathic long QT syndrome. Am Heart J 120, 980-984 (1990)
140. Eden E, Teirstein A and Wiener I: Ventricular arrhythmia induced by vasopressin: torsade de pointes related to vasopressin-induced bradycardia. Mt Sinai J Med 50, 49-51 (1983)
141. + current by therapeutic concentrations of the antispasmodic agent terodiline. Br J Pharmacol 125, 1138-1143 (1998)
142. Connolly M, Astridge P, White E, Morley C and Cowan J: Torsades de pointes ventricular tachycardia and terodiline. Lancet 338, 344-345 (1991)
143. Wang H, Shi H and Wang Z: Nicotine depresses the functions of multiple cardiac potassium channels. Life Sci 65, 143-149 (1999)
144. Geelen P, Drolet B, Rail J, O'Hara GE and Turgeon J: Sildenafil (Viagra®) may lengthen cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. Circulation 100, 1-280 (1999)
145. + channels isolated from Centruroides noxius scorpion venom. FASEB J 13, 953-962 (1999)
146. Startmann H, Walter K and Kennedy H: Torsade de pointes associated with elevated N-acetylprocainamide levels. Am Heart J 109, 375-377 (1985)
147. Werry J, Biederman J, Thisted R, Greenhill L and Ryan N: Resolved: cardiac arrhythmias make desipramine an unacceptable choice in children. J Am Acad Child Adolesc Psychiatry 34, 1239-1245 (1995)
148. Vorperian V, Zhou Z, Mohammad S, Hoon TY, Studennik C and January C: Torsades de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 28, 1556-1561 (1996)
149. Roden D: Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. PACE 21, 1029-1034 (1998)
150. Makkar R, Fromm B, Steinman R, Meissner M and Lehmann M: Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 270, 2590-2597 (1993)
151. Liu X-K, Katchman A, Drici M-D, Ebert S, Ducic I, Morad M and Woosley R: Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther 285, 672-679 (1998)
152. Drici D, Burklow T, Haridasse V, Glazer R and Woosley L: Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 94, 1471-1474 (1996)
153. + channel messenger RNA in rat myometrium during oestrus cycle and in pregnancy. Nature 330, 373-375 (1987)
154. Lehman M, Hardy S, Archibald D and MacNeil D: JTc prolongation with d,l-sotalol in women versus men. Am J Cardiol 83, 354-359 (1999)
155. Kr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 287, 877-883 (1998)
156. Gennari F: Hypokalemia. N Engl J Med 339, 451-458 (1998)
157. Ramee S, White C, Svinarich J, Watson T and Fox R: Torsade de pointes and magnesium deficiency. Am Heart J 109, 164-167 (1985)
158. Akiyama T: Hypocalcemic torsade de pointes. J Electrocardiol 22, 89-92 (1989)
159. Coromilas J: Electrolytes and cardiac arrhythmias. Prog Cardiol 39, 55 (1988)
160. Fredlund B and Olsson S: Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism. Acta Med Scand 213, 213-235 (1983)
161. Isner J, Sours H, Paris A, Ferrans V and Roberts W: Sudden unexpected death in avid dieters using the liquid protein-modified-fast diet: observations in 17 patients and the role of the prolonged QT interval. Circulation 60, 1401-1412 (1979)
162. Cooke R, Chambers J, Singh R, Todd G, Smeeton N, Treasure J and Treasure T: QT interval in anorexia nervosa. Br Heart J 72, 69-73 (1994)
163. Pringle T, Scobie I, Murray K, Kesson C and MacCuish A: Prolongation of the QT interval during therapeutic starvation: a substrate for malignant arrhythmias. Int J Obes 7, 253-261 (1983)
164. Surawicz B: Will QT dispersion play a role in clinical decision-making? J Cardiovasc Pharmacol 7, 777-784 (1996)
165. Tzivoni D, Banaii S, Schuger C, Benhorin J, Keren A, Gottlieb S and Stern S: Treatment of torsade de pointes with magnesium sulfate. Circulation 77, 392-397 (1988)
166. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92, 3381-3386 (1995)
167. Sato T, Hata Y, Yamamoto M, Morita H, Mizuo K, Yamanari H, Saito D and Ohe T: Early afterdepolarizations abolished by potassium channel opener in a patient with idiopathic long QT syndrome. J Cardiovasc Electrophysiol 6, 279-282 (1995)
168. Compton S, Lux R, Ramsey M, Strelich K, Sanguinetti M, Green L, Keating M and Mason J: Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 94, 1018-1022 (1996)
169. Kurita T, Ohe T, Marui N, Aihara N, Takaki H, Kamakura S, Matsihisa M and Shimomura K: Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsade de pointes. Am J Cardiol 69, 628-633 (1992)
170. Priori S, Napolitano C and Schwartz P: Low penetrance in the long-QT syndrome: clinical impact. Circulation 99, 529-533 (1998)